重组人促红细胞生成素治疗对重度颅脑损伤患者康复期血清学指标的影响

Effect of recombinant human erythropoietin therapy on convalescent serological indicators in patients with severe craniocerebral injury

目的:研究重组人促红细胞生成素(rHu-EPO)治疗对重度颅脑损伤患者康复期血清学指标的影响。方法:选择2014年7月~2017年2月在武汉市第五医院接受救治的重型颅脑损伤患者48例,并随机分为接受rHu-EPO联合常规治疗的rHu-EPO组以及接受常规治疗的对照组,治疗前后分别检测血清中神经损伤指标、炎症反应指标、氧化应激反应指标、细胞凋亡指标的含量。结果:两组治疗后14d血清中Tau、S100B、胶质细胞原纤维酸性蛋白(GFAP)、神经元特异性烯醇化酶(NSE)、白介素(IL)-1β、肿瘤坏死因子(TNF)-α、血管细胞黏附分子(VCAM)-1、细胞间黏附分子(ICAM)-1、过氧化脂质(LPO)、晚期氧化蛋白产物(AOPP)、8-iso-PGF2α、sTRAIL、sFas、sFasL的含量均显著低于治疗前且rHu-EPO组患者血清中Tau、S100B、GFAP、NSE、IL-1β、TNF-α、VCAM-1、ICAM-1、LPO、AOPP、8-iso-PGF2α、sTRAIL、sFas、sFasL的含量均显著低于对照组(P<0.05)。结论:rHu-EPO治疗对重度颅脑损伤患者康复期的神经损伤、炎症反应、氧化应激反应以及细胞凋亡均具有显著的改善作用。

Objective：To study the effect of recombinant human erythropoietin（rHu-EPO）therapy on convalescent serological indicators in patients with severe craniocerebral injury.Methods：Patients with severe craniocerebral injury who were treated in the Fifth Hospital in Wuhan between July 2014 and February 2017 were selected and randomly divided into the rHuEPO group who accepted rHu-EPO combined with conventional therapy and the control group.Patients in rHu-EPO group were treated by rHu-EPO combined with conventional therapy,while those in control group who acceptedwere treated by conventional therapy.Before and after treatment,serum levels of nerve injury indexes,inflammation indexes,oxidative stress indexes and apoptosis indexes were measured.Results：Serum Tau,S100 B,GFAP,NSE,IL-1β,TNF-α,VCAM-1,ICAM-1,LPO,AOPP,8-iso-PGF2α,sTRAIL,sFas and sFasL levels of both groups of patients being in 14 days after treatment were significantly lower than those before treatment,and serum Tau,S100 B,GFAP,NSE,IL-1β,TNF-α,VCAM-1,ICAM-1,LPO,AOPP,8-iso-PGF2α,sTRAIL,sFas and sFasL levels of rHu-EPO group were significantly lower than those of control group（P〈0.05）.Conclusions：rHu-EPO therapy can significantly improve the convalescent nerve injury,inflammation,oxidative stress and apoptosis in patients with severe craniocerebral injury.